| Document |
Document Title |
|
WO/2017/109044A1 |
Compounds of the formula (I); wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2017/111152A1 |
Oxadiazole compounds shown by formula (1) [in the formula, G represents a substituted or unsubstituted thiophene ring, furan ring, imidazole ring, oxazole ring, isoxazole ring, thiazole ring, oxadiazole ring, thiadiazole ring, pyridine r...
|
|
WO/2017/103219A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2017/103223A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2017/104782A1 |
In order to provide a method for manufacturing a compound (1) or a pharmaceutically acceptable salt thereof, whereby yield can be improved, cost can be reduced by using an easily obtained, inexpensive starting material and efficiently re...
|
|
WO/2017/102275A1 |
The invention relates to a compound of formula (I), an N-oxide or an agriculturally suitable salt thereof, wherein the variables are as defined in the specification, and their use as herbicides.
|
|
WO/2017/101884A1 |
Disclosed are an indolamine 2,3-dioxygenase inhibitor having the structure of formula (I) and a preparation method and use thereof. The indolamine 2,3-dioxygenase (IDO) inhibitor is a (Z)-N'-hydroxy-N-benzamidine derivative, has a very h...
|
|
WO/2017/097732A1 |
The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2017/097246A1 |
A polymer comprising a repeating unit, which may further comprise one or more repeating units. The present subject matter also relates to a formulation comprising the polymer, and a fullerene, second polymer, or small molecule. The prese...
|
|
WO/2017/093019A1 |
Substituted oxadiazoles for combating phytopathogenic fungi The present invention relates to oxadiazoles of formula (I), or the N-oxides and/or their agriculturally useful salts and to their use for controlling phytopathogenic fungi, and...
|
|
WO/2017/089389A1 |
The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used in the treatment of Human African TRypanosomiasis.
|
|
WO/2017/085100A1 |
Substituted oxadiazoles for combating phytopathogenic fungi. The present invention relates the use of the compounds of the formula I or the N-oxides, or the agriculturally acceptable salts thereof for combating phytopathogenic harmful fu...
|
|
WO/2017/085098A1 |
The present invention relates the compounds of the formula I, or the N-oxides, or the agriculturally acceptable salts thereof and to their use for combating phytopathogenic harmful fungi, wherein the variables are defined as given in the...
|
|
WO/2017/087364A1 |
Novel hydrogen isotope-enriched 1,2,4-oxadiazole benzoic acid compounds, methods of their use and pharmaceutical compositions thereof are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulatio...
|
|
WO/2017/081312A1 |
The present invention relates to novel oxadiazoles of the formula (I), or the N-oxides and/or their agriculturally useful salts and to their use for controlling phytopathogenic fungi, or to a method for combating phytopathogenic harmful ...
|
|
WO/2017/081311A1 |
Substituted oxadiazoles for combating phytopathogenic fungi The present invention relates to novel oxadiazoles of the formula I, or the N-oxides and/or their agriculturally useful salts and to their use for controlling phytopathogenic fu...
|
|
WO/2017/081310A1 |
The present invention relates to novel oxadiazoles of the formula (I), or the N-oxides and/or their agriculturally useful salts and to their use for controlling phytopathogenic fungi, or to a method for combating phytopathogenic harmful ...
|
|
WO/2017/080912A1 |
A thermodynamically stable crystal modification of 2-methyl-N-(5-methyl-1,3,4-oxadiazole-2-yl)-3-(methylsulfony
l)-4-(trifluoromethyl)benzamide is described. Said thermodynamically stable crystal modification has particular advantages re...
|
|
WO/2017/081309A1 |
Substituted oxadiazoles for combating phytopathogenic fungi The present invention relates to oxadiazoles of the formula I, or the N-oxides and/or their agriculturally useful salts and to their use for controlling phytopathogenic fungi, a...
|
|
WO/2017/076739A1 |
The present invention relates to novel oxadiazoles of the formula I, or the N-oxides and/or their agriculturally useful salts and to their use for controlling phytopathogenic fungi, or to a method for combating phytopathogenic harmful fu...
|
|
WO/2017/076742A1 |
The present invention relates to novel oxadiazoles of the formula I or an N-oxide and/or their agriculturally useful salts and to their use for controlling phytopathogenic fungi, or to a method for combating phytopathogenic harmful fungi...
|
|
WO/2017/072247A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2017/070084A1 |
The disclosed subject matter provides N- hydroxylsulfonamide derivative compounds of formulae (I), (II) or (III) as drawn below, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using ...
|
|
WO/2017/068136A1 |
The invention relates to 5,5'-bis(2,4,6-trinitrophenyl)-2,2'-bi(1,3,4-oxadiazole) and bis(2,4,6-trinitrobenzoyl)oxalohydrazide, an energetic active mass comprising or consisting of 5,5'-bis(2,4,6-trinitrophenyl)-2,2'-bi(1,3,4-oxadiazole)...
|
|
WO/2017/065473A1 |
The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicament...
|
|
WO/2017/055146A1 |
Described are acylated N-(1,2,5-oxadiazole-3-yl)-, N-(1,3,4-oxadiazole-2-yl)-, N-(tetrazole-5-yl)- and N-(triazole-5-yl)-aryl carboxamides of formula (I) and the use thereof as herbicides. In said formula (I), R, V, X, Y, and Z are group...
|
|
WO/2017/059303A1 |
Provided herein are vinylogous thioester compounds and methods for using the compounds.
|
|
WO/2017/055175A1 |
A method for synthesizing N-(1,3,4-oxadiazole-2-yl)aryl carboxamides of formula (I) is described, where the substituents represent groups such as hydrogen, alkyl, haloalkyl or aryl.
|
|
WO/2017/055473A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially fungicides.
|
|
WO/2017/055469A1 |
Compounds of the formula (I) wherein, the substituents are as defined in claim 1, useful as a pesticides, especially as fungicides.
|
|
WO/2017/050969A1 |
The present invention relates to modified fumarate molecules capable of activating HO-1 protein expression, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory and cardiovas...
|
|
WO/2017/049245A2 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2017/035662A1 |
Described herein is a genetic modifier of cystic fibrosis (CF), which may serve as a predictor of the efficacy of a CFTR-directed therapy. SNPs rs7512462 or rs2869027 in non-coding regions of SLC26A9 are shown to correlate with CF lung d...
|
|
WO/2017/032728A1 |
The invention relates to substituted ketoxime benzoylamides of general formula (I) as herbicides. In said formula (I), R1', R2', X, Y and W represent groups such as hydrogen, organic groups such as alkyl, and other groups such as halogen...
|
|
WO/2017/031325A1 |
The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, co...
|
|
WO/2017/018805A1 |
The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments...
|
|
WO/2017/018803A1 |
The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparati...
|
|
WO/2017/018804A1 |
The present invention relates to: a novel compound having a histone deacetylase 6 (HDAC6) inhibitory activity; an optical isomer thereof or a pharmaceutically acceptable salt thereof; a use thereof for preparing a therapeutic pharmaceuti...
|
|
WO/2017/010399A1 |
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...
|
|
WO/2017/005564A1 |
The invention relates to N-(1,3,4-oxadiazol-2-yl) aryl carboxamide derivatives of the general formula (I) as herbicides. In said formula (I), V, X, and Z represent groups such as hydrogen, and organic groups such as alkyl, and other grou...
|
|
WO/2017/004964A1 |
The present invention provides a novel preparation method of a 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid as a drug for preventing muscular dystrophy and an intermediate compound. The preparation method has a reasonable prod...
|
|
WO/2017/004608A1 |
The invention is directed to Compounds of Formula (I): wherein each variable is defined herein, as well as methods of making and using the compounds as agonists of S1P1 and/or S1P5 for instance for treating graft versus host disease and ...
|
|
WO/2017/004610A1 |
Disclosed are tercyclic S1P3-sparing, S1P1 receptor agonists, as well as processes for making and methods of using the same. Poor solubility and cationic amphiphilic drug- likeness were liabilities identified for a lead series of S1P3-sp...
|
|
WO/2016/198507A1 |
Compound of formula (I) wherein A is selected from (i), where RF1 is H or F; (ii); (iii) a N-containing C6 heteroaryl group; and B is (B), where X1 is either CRF2 or N, where RF2 is H or F; X2 is either CR3 or N, where R3 is selected fro...
|
|
WO/2016/201168A1 |
The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, co...
|
|
WO/2016/197959A1 |
The present invention relates to the compound of formula (I) used for detecting dihydroorotate dehydrogenase. In formula (I), A is pigment group, L is link arm, R is specific binding ligand for dihydroorotate dehydrogenase. The compound ...
|
|
WO/2016/193470A1 |
The present invention relates to compounds according to Formula (I): or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases.
|
|
WO/2016/189877A1 |
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...
|
|
WO/2016/187046A1 |
Methods for treating various cancers by administering one or more compounds that target the dimeric protein survivin are disclosed. Pharmaceutical compositions containing such compounds are also disclosed, along with general methods of i...
|
|
WO/2016/172425A1 |
Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. Formula I is exemplified below: Formula (i)
|
